Litcius/Paper detail

Senescent T cells: a potential biomarker and target for cancer therapy

Jie Zhang, Tianhui He, Lixiang Xue, Hongyan Guo

2021EBioMedicine174 citationsDOIOpen Access PDF

Abstract

The failure of T cells to eradicate tumour cells in the tumour microenvironment is mainly due to the dysfunction of T cells. Senescent T cells, with defects in proliferation and effector functions, accumulate in ageing, chronic viral infections, and autoimmune disorders where antigen stimulation persists. Increasing evidence suggests that inducing T cell senescence is a key strategy used by malignant tumours to evade immune surveillance. In this review, we summarize the general features, functional regulation, and signalling network of senescent T cells in tumour development and highlight their potential as prognostic biomarkers in multiple cancer treatments, including chemotherapy, radiotherapy, and immunotherapy. Moreover, we discuss possible therapeutic strategies for preventing or rejuvenating senescence in tumour-specific T cells. Understanding these critical issues may provide novel strategies to enhance cancer immunotherapy.

Topics & Concepts

ImmunotherapySenescenceImmune systemCancerImmunologyEffectorCancer researchCancer immunotherapyT cellChimeric antigen receptorBiomarkerRadiation therapyBiologyMedicineCancer cellInternal medicineBiochemistryCAR-T cell therapy researchImmune Cell Function and InteractionImmunotherapy and Immune Responses
Senescent T cells: a potential biomarker and target for cancer therapy | Litcius